Ask AI

Optimizing Patient-Centered Care for Relapsed/Refractory CLL With the Latest Evidence and Guideline Updates: Precision Education With Real-world Insights

Start Activity
Video
Video Start Activity
This activity is available for 1.00 CME/CE credit(s).

Released: September 08, 2026

Expiration: March 07, 2027

See Activity Collection

Step 1 of 5

1 Pre Assessment 2 Video 3 Post Assessment 4 Evaluation 5 Credit

In this on-demand webcast, an expert reviews contemporary treatment strategies for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with an emphasis on how prior therapy, mechanisms of resistance, comorbidities, disease characteristics, and patient preferences inform treatment sequencing. The faculty examines evidence supporting covalent and noncovalent BTK inhibitors, BCL-2 inhibitor–based regimens, and retreatment approaches; discusses pivotal trials including MURANO, ELEVATE-RR, ALPINE, and the BRUIN CLL studies; and addresses the evolving role of pirtobrutinib and CAR T-cell therapy for patients with increasingly treatment-resistant disease. The activity also reviews practical management of treatment-related toxicities, including tumor lysis syndrome, bleeding, atrial fibrillation, hypertension, and infusion reactions, as well as strategies to prevent disease flare when transitioning between therapies. Finally, emerging approaches such as BTK degraders and bispecific antibodies are considered alongside patient-centered factors, providing learners with a framework for individualizing therapy across successive lines of CLL/SLL treatment.

Nitin Jain
Nitin Jain, MD
Patient Centered Care for RR CLL

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
Begin Your Video
1.

How many people with CLL/SLL do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Please rate your level of agreement with the following statement. I am very confident in applying shared decision-making strategies to support patient QoL and engagement in care for R/R CLL/SLL.

4.

Patient Case 1



  • An 84-yr-old man with R/R CLL previously received ibrutinib for 6 yr, followed by venetoclax + rituximab, achieving a partial response 

  • He now presents with progressive lymphocytosis and symptomatic adenopathy 8 mo after completing venetoclax 

  • Molecular testing reveals a BTK C481S mutation and no BCL2 mutation

  • He has well-controlled hypertension and prefers oral therapy

What is the most appropriate next step in management of this patient?

5.

Patient Case 2



  • A 75-yr-old woman with R/R CLL discontinued ibrutinib due to arthralgias after being on treatment for 2 yr 

  • She was observed for 9 mo off therapy but then developed progressive disease requiring treatment

  • She has stage 2 CKD (CrCl 35 mL/min), requires anticoagulation, and expresses concern about tumor lysis syndrome (TLS) monitoring logistics

  • She prefers to avoid hospitalization

Which of the following is the most appropriate next therapy?

6.

Patient Case 3



  • A 62-yr-old patient with R/R CLL has progressed after both a covalent BTK inhibitor and venetoclax

  • He is interested in therapies that may provide durable remission and is willing to travel for treatment

  • No significant comorbidities are present

Which of the following is the most appropriate counseling regarding CAR T-cell therapy in this setting?

7.

Patient Case 4



  • A 70-yr-old patient with R/R CLL progressed on acalabrutinib and is now being evaluated for next-line therapy

  • He has severe renal impairment (CrCl 25 mL/min) and lives far from a treatment center

  • He expresses concern about hospitalization and asks about “newer targeted pills vs CAR T," including investigational options such as BTK degraders

Which of the following is the most appropriate counseling regarding enrollment in a clinical trial for a BTK degrader?

Begin Your Video